- Policy
- NHI turns to deficit with a mere 2.6% coverage improvement
- by Lee, Jeong-Hwan Aug 26, 2022 05:35am
- With the new government preparing for complete reorganization and faceoff of the national health insurance coverage enhancement project ‘Moon Jae-In Care,' the ruling party criticized that Mooncare's implementation turned the current NHI balance into a deficit while raising the coverage rate by only a mere 2.6% points. Also, the party cr
- Policy
- Pts with osteopenia need screening tx
- by Kim, Jung-Ju Aug 26, 2022 05:35am
- The National Evidence-based Healthcare Collaborating Agency (Director Han Kwang-hyeop, NECA) analyzed the drug effect in osteopenia patients and developed a fracture risk prediction model and published the results of the study on the 25th. As aging rapidly progresses worldwide, the prevalence of osteopenia and osteoporosis is rapidly incre
- Policy
- MET mutant anticancer drug Tepmetko challenges
- by Lee, Tak-Sun Aug 25, 2022 05:52am
- Following the MET mutant anti-cancer drug Tabrecta, which landed in Korea last year, Tepmetko is also undergoing a review. MET mutations occur only in about 3-4% of non-small cell lung cancer patients, but the prognosis is poor, so there is a desperate need for treatments that are covered by benefits. According to an industry on the 24t
- Policy
- Entry of HER2-low breast cancer Tx imminent in Korea
- by Lee, Hye-Kyung Aug 25, 2022 05:52am
- Daiichi Sankyo Korea and AstraZeneca Korea’s human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) “Enhertu Inj (trastuzumab deruxtecan)” is expected to be approved in Korea soon. This imminent entry of the first treatment for HER2-low breast cancer in Korea attracting much attention. According to i
- Policy
- 3rd gen ALK NSCLC drug Lorviqua to be listed on next month
- by Lee, Tak-Sun Aug 25, 2022 05:52am
- Pfizer's third-generation non-small cell lung cancer treatment, Lorviqua, will be listed next month (September). As this drug can be used for non-small cell lung cancer that does not respond to ALK-positive first- and second-generation drugs, patients' treatment opportunities are expected to expand with registration. The HIRA announced on the
- Policy
- Benefit for Sigmart 48mg will be newly established on Sept.
- by Kim, Jung-Ju Aug 25, 2022 05:52am
- Including Sigmart 48mg, JW Pharmaceutical's angina treatment, Nitroglycerin such as Nicorandil's drug, Elyson's Perlinganit 0.1% injection, which is used as a blood pressure control before and after surgery, and Verapamil HCl, Sanofi-Aventis Korea's Adenosine, are expected to be reimbursed next month. The benefits of Mycophenolate mofetil inj
- Policy
- All domestic restrictions on PVA cut are agreed
- by Lee, Tak-Sun Aug 24, 2022 05:56am
- Jeong Hae-min, head of the NHIS Pharmaceutical Management Office, is briefing with the Korea Special Press Association on the 23rd. In the PVA negotiations that reflect this year's revised guidelines, all domestic pharmaceutical companies agreed with the NHIS. Initially, negotiations with some domestic pharmaceutical companies were expected t
- Policy
- Gov't “will reinvestigate overused reimbursed items”
- by Lee, Jeong-Hwan Aug 24, 2022 05:55am
- The government will begin discussions on fiscal reform of the National Health Insurance areviewreivew the overused healthcare items ng on already-listed reimbursed items to expand essential healthcare and ensure the sustainability of NHI finances. On the 23rd, the Ministry of Health and Welfare launched and held the first meeting of the N
- Policy
- Na Kyung-won is considering being the Minister of Health
- by Lee, Jeong-Hwan Aug 23, 2022 06:04am
- The opposition party is immediately criticizing the new government as Yoon Seok-yeol's office is reportedly considering Na Kyung-won, a former lawmaker with four-term experience, as a candidate for the next health and welfare minister. According to political circles of the ruling and opposition parties on the 22nd, President Yoon Seok-ye
- Policy
- Bill for 'state compensation for Paxlovid's side effects'
- by Lee, Jeong-Hwan Aug 23, 2022 06:04am
- A bill proposing the government's compensation for damages arising from the administration of COVID-19 treatments that were granted Emergency Use Authorization (EUA) such as Paxlovid or Lagevrio etc. has been filed. On the 22nd, People Power Party member Mi-Ae Kim proposed a bill as representative for the partial revision of the “Special Ac
